Sorafenib

Catalog No.S7397 Synonyms: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 134 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NIKwe3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXOSmdKSzVyPUCuNFAxODB|MEOg{txO MYHTRW5ITVJ?
MONO-MAC-6 NF3NTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jL[GlEPTB;MD6wNFQyQCEQvF2= NVjM[3hxW0GQR1XS
ALL-PO M3zOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEOxPFQh|ryP NHS1Vm5USU6JRWK=
NKM-1 NFTjd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHtdWhTUUN3ME2wMlA4PDF4IN88US=> MnHoV2FPT0WU
CGTH-W-1 M3TTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEWyOpJKSzVyPUCuNlUxOjJizszN MmriV2FPT0WU
BB65-RCC MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljITWM2OD1yLkS3NFc{KM7:TR?= M2jlOXNCVkeHUh?=
NOS-1 NVvNbHJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ZTZE6UUN3ME2wMlU3OzZizszN Mnv0V2FPT0WU
SH-4 NInjcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nkdmlEPTB;MD62OVYyOyEQvF2= MX;TRW5ITVJ?
HOP-62 NXvBeWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTETWM2OD1yLki1NFg5KM7:TR?= MVHTRW5ITVJ?
HCC2998 NYrvXIdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEixOmtKSzVyPUCuPFg5OThizszN NIT0NmhUSU6JRWK=
GDM-1 M3LUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi2TIpKSzVyPUCuPVA3QThizszN NFi5WpFUSU6JRWK=
KM12 NYjyV2ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnrUFhqUUN3ME2xMlAzODl6IN88US=> NFX6WYtUSU6JRWK=
LB2518-MEL M3Hucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrDUG1KSzVyPUGuNlA5ODlizszN NInzc2pUSU6JRWK=
NCI-H1436 NFfPXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fqZWlEPTB;MT6yNVY4QCEQvF2= NW\KbYR1W0GQR1XS
EM-2 NVvQflNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzoTWM2OD1zLkO1OVc5KM7:TR?= NHzncYJUSU6JRWK=
LAMA-84 M{K4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXBPHdFUUN3ME2xMlM4PjR6IN88US=> MmDwV2FPT0WU
KG-1 NGnG[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC2c2YzUUN3ME2xMlQ4QTN3IN88US=> NYr0dm81W0GQR1XS
A388 NVW1eHN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT6cWVKSzVyPUGuOVkyPjVizszN NFXuNlZUSU6JRWK=
no-10 NYTZOnRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSxTWM2OD1zLk[xO|I3KM7:TR?= M4H2cHNCVkeHUh?=
SF126 NF\PSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHQSlFKSzVyPUGuOlM5OTJizszN NIT4O2pUSU6JRWK=
MEG-01 M3robmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P3eWlEPTB;MT64NFk5KM7:TR?= M{O5PHNCVkeHUh?=
A3-KAW NF\ubIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHybG1YUUN3ME2xMlg5PDJizszN NU\pR5pVW0GQR1XS
D-247MG NI\qVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlToTWM2OD1{LkG0OFgh|ryP MkPOV2FPT0WU
OVCAR-4 NGTYcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjFTWM2OD1{LkKxN|k{KM7:TR?= M3rMRXNCVkeHUh?=
NCI-SNU-1 M3S3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED4VmFKSzVyPUKuN|E3OiEQvF2= M4HycHNCVkeHUh?=
NCI-H2171 M334fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TxeWlEPTB;Mj6zPVc3PCEQvF2= NUXm[2VmW0GQR1XS
SIG-M5 M4m1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXXTWM2OD1{LkSyNlQzKM7:TR?= MlXtV2FPT0WU
BE-13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomyTWM2OD1{Lk[5OlA6KM7:TR?= NIfyO2pUSU6JRWK=
K052 M4PoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT2TWM2OD1{Lke0OlE3KM7:TR?= MVTTRW5ITVJ?
L-540 M{HNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwN{W3PFkh|ryP MVzTRW5ITVJ?
KMOE-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPoTWM2OD1{LkixN|Uh|ryP NWDDWW1HW0GQR1XS
MFH-ino NYC5fVlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\hTWM2OD1{LkmyNVg2KM7:TR?= MYLTRW5ITVJ?
HL-60 M{HiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W0Z2lEPTB;Mz6wOlI6QSEQvF2= MYXTRW5ITVJ?
HCC2218 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNwMUKwNFMh|ryP MXrTRW5ITVJ?
TE-5 NIW0NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwMUOxOlIh|ryP MWjTRW5ITVJ?
MZ1-PC Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvhXlFKSzVyPUOuOFc2ODlizszN NF7V[FlUSU6JRWK=
MRK-nu-1 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNwNkG0Olgh|ryP NYrLVJU{W0GQR1XS
MZ7-mel MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH3TWM2OD1|Lk[2NFk6KM7:TR?= MmrXV2FPT0WU
BC-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjlelVlUUN3ME2zMlc1ODJizszN NF\JfVFUSU6JRWK=
ST486 M4GzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjvTWM2OD1|LkizOlc{KM7:TR?= NGLwNpZUSU6JRWK=
KS-1 NVrSN4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHXcJNLUUN3ME2zMlg5OTl6IN88US=> Mo\VV2FPT0WU
SK-NEP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\PdXRKSzVyPUSuNVY5OTVizszN NHnicI1USU6JRWK=
BC-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3h[4JKSzVyPUSuNlM{QTFizszN MVnTRW5ITVJ?
NCI-H1581 NHXlS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7abZlJUUN3ME20MlI5Pzl6IN88US=> NFPLR21USU6JRWK=
MHH-PREB-1 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrPOWhKSzVyPUSuOFA1QDRizszN NH6yW3FUSU6JRWK=
NOMO-1 MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH6W5VZUUN3ME20MlQ5QTB3IN88US=> NHLibWxUSU6JRWK=
QIMR-WIL NY\nV252T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm3TWM2OD13LkC3Nlk1KM7:TR?= NYe5bmU5W0GQR1XS
SF539 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q4NmlEPTB;NT6xN|IzPyEQvF2= MlPwV2FPT0WU
TE-12 NXjYe3NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3TXlZKSzVyPUWuNlQ6OjlizszN NV[5WXFrW0GQR1XS
NCI-H510A MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTVwNEG2PFUh|ryP NV7yZmc6W0GQR1XS
JAR MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTtdo9EUUN3ME21MlUxQDJ2IN88US=> NWLhbppoW0GQR1XS
no-11 NWTSfWZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnITWM2OD13LkezOVY5KM7:TR?= MUPTRW5ITVJ?
BV-173 NGS2[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTVwOUW2PFIh|ryP MnjIV2FPT0WU
SR MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q4bGlEPTB;Nj6wNFY4QCEQvF2= NIqwfXNUSU6JRWK=
MOLT-16 M2HLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDHTWM2OD14LkK1NlY3KM7:TR?= M{WxPHNCVkeHUh?=
MZ2-MEL M2DQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHPSXZmUUN3ME22MlMyQDN7IN88US=> NFW4TZFUSU6JRWK=
SW954 NGLOWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD1cXlmUUN3ME22MlQ2QDZ4IN88US=> MYHTRW5ITVJ?
ML-2 M{f2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M124dWlEPTB;Nj61Nlg1QSEQvF2= MWPTRW5ITVJ?
OCI-AML2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHDZWIyUUN3ME22MlYyODZ{IN88US=> NUf5PItEW0GQR1XS
SIMA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qxRmlEPTB;Nz6wNFExOSEQvF2= NW\VXpB6W0GQR1XS
DOHH-2 NH3OdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3sUnNKSzVyPUeuNFU3PzZizszN MXnTRW5ITVJ?
697 NUWyN4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTdwMEW5PFkh|ryP M2S0e3NCVkeHUh?=
NB1 Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTdwNEC0NFch|ryP MlvMV2FPT0WU
D-392MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTaeFFKSzVyPUeuOlI3PjNizszN MYTTRW5ITVJ?
ES8 MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTdwN{[1NFMh|ryP MmPTV2FPT0WU
RPMI-8226 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvXTWM2OD15Lki0OVEyKM7:TR?= MXLTRW5ITVJ?
IST-MEL1 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTxWnZqUUN3ME24MlQxODB{IN88US=> MnzLV2FPT0WU
NB14 NIDKPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y0T2lEPTB;OD62N|E{OyEQvF2= NVnsOHFXW0GQR1XS
HD-MY-Z MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRThwNkO3OFYh|ryP MULTRW5ITVJ?
TE-10 M1zVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfue3ZKSzVyPUiuO|Y{PTNizszN MoLhV2FPT0WU
LC-1F MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\5UmlEPTB;OT6xNFg{PCEQvF2= NHLCTFJUSU6JRWK=
OS-RC-2 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTlwMUGyOFMh|ryP NV\Dd3JoW0GQR1XS
NCI-SNU-16 NVHSdFJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPXTWM2OD17LkKxNFI3KM7:TR?= NWm1XYpHW0GQR1XS
SHP-77 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HxdWlEPTB;OT63NVY3OiEQvF2= M4LlbnNCVkeHUh?=
A4-Fuk MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fMemlEPTB;OT63OVYyKM7:TR?= NVLOblE6W0GQR1XS
NB6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTlwN{[wNlkh|ryP Mle3V2FPT0WU
JiyoyeP-2003 NXfDT21LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnziTWM2OD1zMD60O|Q2KM7:TR?= M3TS[nNCVkeHUh?=
DMS-114 NWPHZ493T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:ySW9KSzVyPUGwMlU1PDFizszN NFr3UIJUSU6JRWK=
NB7 NF7S[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;wTWM2OD1zMD63OVI3KM7:TR?= MXjTRW5ITVJ?
NCI-H747 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPFVZZqUUN3ME2xNU4yOjF4IN88US=> M{HhUnNCVkeHUh?=
HH MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jnPWlEPTB;MUGuN|g4PiEQvF2= M2DaWnNCVkeHUh?=
EW-18 NITuZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvQSZRHUUN3ME2xNU46ODR2IN88US=> MmLFV2FPT0WU
CHP-126 NVnaVY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFzLkm3N|gh|ryP M3WxfnNCVkeHUh?=
NTERA-S-cl-D1 NFvQU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\qV|dPUUN3ME2xNk4xOjd6IN88US=> M4G5[HNCVkeHUh?=
DEL NF\DRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\xVXR3UUN3ME2xNk4xQTh3IN88US=> NEHSZZVUSU6JRWK=
LU-139 MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf6bIF{UUN3ME2xNk42PDF|IN88US=> MWDTRW5ITVJ?
P30-OHK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF{LkW0O|kh|ryP NXrNNIV2W0GQR1XS
NCI-H1522 M3LIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXYXYF[UUN3ME2xNk44PDZizszN NUjZXIRMW0GQR1XS
NCI-H1299 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF|LkK5NVEh|ryP NE\BeZJUSU6JRWK=
UACC-257 M1zh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPtRmhMUUN3ME2xN{42OTJ4IN88US=> NVL4PW1LW0GQR1XS
Calu-6 NIfCVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fPW2lEPTB;MUOuOlA1PiEQvF2= NWWxVYlqW0GQR1XS
NCI-H1882 M{iy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XqXWlEPTB;MUOuPFU2PSEQvF2= NUXDXIExW0GQR1XS
BB30-HNC NVHvcWtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTyW49JUUN3ME2xOE4xPjB7IN88US=> NYTWNG9vW0GQR1XS
ES1 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;TdmlEPTB;MUSuNVU2OSEQvF2= NWLhSol2W0GQR1XS
NCI-H1694 M2X1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W4ZWlEPTB;MUSuOFgyOSEQvF2= MWrTRW5ITVJ?
IST-SL1 NILJcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonZTWM2OD1zND65OlE3KM7:TR?= NWHhS3RQW0GQR1XS
ECC4 NF7PWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{myOmlEPTB;MUWuNFU2QCEQvF2= MlTlV2FPT0WU
MDA-MB-134-VI NY\GN45ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHUTWM2OD1zNT60NVMyKM7:TR?= NFfsfXFUSU6JRWK=
SCH NVH5UJROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTy[odWUUN3ME2xOU41PzJ6IN88US=> NEXyfYdUSU6JRWK=
SK-N-FI NFzKfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXURY96UUN3ME2xOU43PTN2IN88US=> MmXIV2FPT0WU
HDLM-2 NHvRc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G3S2lEPTB;MU[uNFcyPCEQvF2= NXexVJkxW0GQR1XS
Ramos-2G6-4C10 M3vTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLsS2VLUUN3ME2xOk4yOjl5IN88US=> NFz1[VFUSU6JRWK=
EW-24 M3\SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXwRow5UUN3ME2xOk4yPjZzIN88US=> MlK3V2FPT0WU
NCI-H2141 M3LSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XTPGlEPTB;MU[uNVg6KM7:TR?= MVLTRW5ITVJ?
LC4-1 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTkd|BpUUN3ME2xOk43OTF7IN88US=> NVLYXJRiW0GQR1XS
HT-144 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHiw[5pKSzVyPUG3MlAxPiEQvF2= M2HyOnNCVkeHUh?=
SK-MEL-1 M4\OWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rPeGlEPTB;MUeuNFA4OiEQvF2= M331TXNCVkeHUh?=
SCC-15 NUDlfnAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPFTWM2OD1zNz6xOlM5KM7:TR?= M4fqeHNCVkeHUh?=
C8166 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGyTWM2OD1zNz62PFM{KM7:TR?= NILsWYVUSU6JRWK=
GOTO NH3SO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF5LkizOFQh|ryP NEHvS|lUSU6JRWK=
COR-L279 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jub2lEPTB;MUiuNVM3OiEQvF2= NYKycld2W0GQR1XS
K-562 NITvO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrXTWM2OD1zOD63NVQ{KM7:TR?= NYLJZ216W0GQR1XS
ES3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF6LkiwOFEh|ryP NE\MNHpUSU6JRWK=
LU-165 NX;IZYFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nBbGlEPTB;MUmuO|AxQCEQvF2= NGTqUpJUSU6JRWK=
KM-H2 NWrRV3U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jXO2lEPTB;MkCuN|E5PCEQvF2= NFXZ[GZUSU6JRWK=
RL Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HndWlEPTB;MkCuPVY6OiEQvF2= NVHIbWZjW0GQR1XS
EW-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETOWYZKSzVyPUKxMlE5QDlizszN NFu4e5VUSU6JRWK=
A101D M1W1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnjeZNKSzVyPUKxMlM4PTJizszN M4PmV3NCVkeHUh?=
HUTU-80 NYTtWXJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\DTWM2OD1{MT6zPVQ3KM7:TR?= NGrpfGtUSU6JRWK=
NCI-H23 M4Pwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj3TWM2OD1{MT6zPVkzKM7:TR?= MWLTRW5ITVJ?
PF-382 M4DXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG4O5pKSzVyPUKxMlQ1ODNizszN NEnGWXdUSU6JRWK=
LB373-MEL-D MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzDTWM2OD1{MT61OlE2KM7:TR?= M4jxUHNCVkeHUh?=
TE-8 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfrTWM2OD1{MT62N|k1KM7:TR?= NHnGO29USU6JRWK=
TE-9 NIHtXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvvTWM2OD1{MT64OVE{KM7:TR?= MYXTRW5ITVJ?
Daudi MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXaUZJKSzVyPUKxMlk{ODRizszN MVjTRW5ITVJ?
D-542MG NIf5VoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzlfmI6UUN3ME2yNk4xOjV4IN88US=> M1e2ZnNCVkeHUh?=
U-698-M NH;pR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3VSlZKSzVyPUKyMlQ3ODNizszN M4TsOXNCVkeHUh?=
ES6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nYZ2lEPTB;MkKuO|M3PiEQvF2= MX\TRW5ITVJ?
DU-4475 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3LTWM2OD1{Mz64PFk4KM7:TR?= NFrneXhUSU6JRWK=
ECC12 M4HNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXYSIF5UUN3ME2yOE4zQDB|IN88US=> NXnqO41SW0GQR1XS
C2BBe1 M37wS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfkTWM2OD1{ND6zNlM6KM7:TR?= NFrVcW9USU6JRWK=
IST-SL2 NYHGOHZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfmbZE1UUN3ME2yOE41OzZ{IN88US=> MYDTRW5ITVJ?
DJM-1 NVXmZXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPRRo1GUUN3ME2yOE42OjJzIN88US=> NYTHcXhpW0GQR1XS
DMS-153 MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWiwNGFPUUN3ME2yOE45PjF2IN88US=> NVzzOmVRW0GQR1XS
NB13 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ3LkCyOlUh|ryP M{[0U3NCVkeHUh?=
SK-N-DZ NXz4NlZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ4LkO0NVQh|ryP M3Pad3NCVkeHUh?=
COR-L88 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\DTWM2OD1{Nj61O|k3KM7:TR?= MUnTRW5ITVJ?
LU-65 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTsTWM2OD1{Nj64OVM2KM7:TR?= NWLFc4syW0GQR1XS
TGBC1TKB M1PaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrKTWM2OD1{Nj65PFI5KM7:TR?= NYftU482W0GQR1XS
THP-1 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTyRY1KSzVyPUK3MlIyPDFizszN NF;ENVhUSU6JRWK=
ONS-76 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTCXWtKSzVyPUK3MlM{OiEQvF2= NUDC[XN1W0GQR1XS
LC-2-ad M1OyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\6Xm5IUUN3ME2yO{43OjNzIN88US=> NYTXd4JnW0GQR1XS
EW-13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ7LkG3OFYh|ryP M{TMTnNCVkeHUh?=
MS-1 NXn0OXVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXIWVFQUUN3ME2zNE44Ojd6IN88US=> NFT2Z3NUSU6JRWK=
NCI-H2227 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HidWlEPTB;M{CuPVgxPiEQvF2= NXWwU5FbW0GQR1XS
LXF-289 NWK0cppkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknMTWM2OD1|MT60OFkzKM7:TR?= NX;NRnBMW0GQR1XS
MC116 NHvmTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnyTWM2OD1|Mj6wPFI3KM7:TR?= NV\tOnBJW0GQR1XS
EVSA-T M1y5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN{LkK1PFUh|ryP MUTTRW5ITVJ?
CTB-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfCcWtKSzVyPUOzMlEyODFizszN NIjteXFUSU6JRWK=
COLO-320-HSR NHv3flNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXhPGZDUUN3ME2zN{4yPjB|IN88US=> NGLL[YpUSU6JRWK=
NCI-H2196 M4q1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj6[G5MUUN3ME2zN{4zPTV5IN88US=> NH;WfIlUSU6JRWK=
LB2241-RCC NY\kTY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmraTWM2OD1|Mz6zNVM2KM7:TR?= NG\pbWdUSU6JRWK=
LS-513 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\Eb|FwUUN3ME2zN{45PjN6IN88US=> Mn\pV2FPT0WU
LP-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN|Lkm5OVYh|ryP NVvLWJVnW0GQR1XS
A253 M2m2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLTS41UUUN3ME2zOE4zOjl4IN88US=> MoDSV2FPT0WU
SK-MM-2 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLt[YFGUUN3ME2zOE46PDVzIN88US=> MV\TRW5ITVJ?
NCI-H1963 NV;tPZR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rnVGlEPTB;M{WuN|A4OiEQvF2= Mn\OV2FPT0WU
MMAC-SF NIrUdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj0cWRzUUN3ME2zOU45Pzh3IN88US=> NIjhVG1USU6JRWK=
LB831-BLC M{fVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fQOmlEPTB;M{[uNFY2PCEQvF2= NWPzdG5QW0GQR1XS
WSU-NHL NULPVnp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN4LkG2OEDPxE1? MXPTRW5ITVJ?
CESS M3HWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXGUo1YUUN3ME2zOk4zQDR6IN88US=> M3zE[HNCVkeHUh?=
NEC8 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfPeFF{UUN3ME2zOk42QDN3IN88US=> NXHWfnR5W0GQR1XS
KNS-42 NVrpNGZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;NSlBKSzVyPUO3MlEzOzdizszN MYjTRW5ITVJ?
MHH-CALL-2 NVLQWFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH4UXpCUUN3ME2zO{4yQDJzIN88US=> MlHTV2FPT0WU
K5 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\1TWM2OD1|OD60N{DPxE1? M1Lt[XNCVkeHUh?=
CP66-MEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHjOZBKSzVyPUO5MlA4OzNizszN NVG4SppXW0GQR1XS
OPM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fYRWlEPTB;M{muPFQ{OiEQvF2= NFnDUGtUSU6JRWK=
IST-MES1 NXfhUpVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTRyLkOwPVYh|ryP NWXRVItLW0GQR1XS
EC-GI-10 NHS2TIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTHblZKSzVyPUSxMlU5ODVizszN MojrV2FPT0WU
CTV-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDETWM2OD12Mj64OFA3KM7:TR?= NI\OVXFUSU6JRWK=
DG-75 NGTvfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHNNm5KSzVyPUSzMlc2QTVizszN NFzESWNUSU6JRWK=
KNS-81-FD MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR3LkSwOVgh|ryP MV;TRW5ITVJ?
NCI-H82 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrOVXlKSzVyPUS1MlU4PThizszN M2\1fnNCVkeHUh?=
RPMI-8866 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jO[GlEPTB;NE[uNVg4OyEQvF2= MnPlV2FPT0WU
ACN Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjDTWM2OD12Nj60N|Qh|ryP NX3iOFZ{W0GQR1XS
NCI-H1395 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;2TWNiUUN3ME20Ok41PzV4IN88US=> NXzsRnhEW0GQR1XS
NCI-H209 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTR5LkG0NFUh|ryP MnrPV2FPT0WU
TGW NHjzWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPQd2d{UUN3ME20PU4xPzlzIN88US=> M2SycnNCVkeHUh?=
NCI-H748 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3mwSmlEPTB;NEmuOFc2OyEQvF2= NHPwPHNUSU6JRWK=
EKVX NWX5Nox3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f4RWlEPTB;NEmuOlYzQCEQvF2= M{f5S3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

+ Expand
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 400+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03780634 Not yet recruiting Hepatocellular Carcinoma Sun Yat-sen University|Kaiping Central Hospital|Guangzhou No.12 People''s Hospital April 1 2019 Phase 2
NCT03780634 Not yet recruiting Hepatocellular Carcinoma Sun Yat-sen University|Kaiping Central Hospital|Guangzhou No.12 People''s Hospital April 1 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03644511 Recruiting Hepatocellular Carcinoma Bayer February 28 2019 --
NCT03606590 Recruiting Hepatocellular Carcinoma NovoCure GmbH|NovoCure Ltd. February 15 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products0

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID